Search
Search Results
##search.searchResults.foundPlural##
-
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1428PDF: 879HTML: 223 -
Acquired Sideroblastic Anemia: An exploratory Comparative Statistical Analysis Between Clonal and Non-clonal cases Acquired Sideroblastic Anemia
1134PDF: 651HTML: 464 -
TUBERCULOSIS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS.
2695PDF: 976HTML: 3722 -
miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS
775PDF: 899PDF Supp. Files: 83HTML: 244 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
2053PDF: 108HTML: 29 -
WHAT ARE FUNGAL INFECTIONS?
4286PDF: 2447HTML: 27647de Pauw: 254 -
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4497PDF: 1663HTML: 4201Tables and Images: 250 -
Anemia in the elderly: not always what it seems.
3355PDF: 1101HTML: 1788Figure 1: 195Figure 1 revised: 194 -
NASAL NK/T- CELL LYMPHOMA. COMPARATIVE ANALYSIS OF A MEXICAN POPULATION
1816PDF: 1011HTML: 1823Tables: 189 -
ROLE OF CYTOKINES AS MOLECULAR MARKER OF DENGUE SEVERITY
3242PDF: 1195HTML: 485 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1784PDF: 582HTML: 354 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7752PDF: 2460HTML: 2101Table 1.: 233Table 2.: 242Table 3.: 224Table 4.: 218 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
150PDF: 129HTML: 38 -
TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL Sirapat Rungwittayatiwat1, Paisarn Boonsakan2, Pichika Chantrathammachart1, Teeraya Puavilai1, Sulada Pukiat1, Sithakom Phusanti1,3, Kochawan Boonyawat1, Pathawut Wacharapornin1, Pantep Angchaisuksiri1, Artit Ungkanont1,3, Suporn Chuncharunee1 Pimjai Niparuck1
1218PDF: 567HTML: 237 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
733PDF: 276Html: 36 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4004PDF: 1144HTML: 463 -
RECENT ADVANCES IN THE 5Q- SYNDROME
2870PDF: 1854HTML: 3733Pellagatti Fig 1: 232Pellagatti Fig. 2: 227 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3362PDF: 798HTML: 3015Figure 1a and 1b: 164Figure 2: 171Figure 3: 191Figure 4: 171Figure 5: 174Tables 1-5: 160 -
Parasitic hypereosinophilia in childhood: a diagnostic challenge
2632PDF: 831HTML: 346Figure 1: 179 -
-
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1426PDF: 829HTML: 1025 -
I INCREASED RISK OF LYMPHOMA IN MEN INFECTED WITH TUBERCULOSIS
1202PDF: 507HTML: 400 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1824PDF: 596HTML: 340 -
The association of rheumatoid arthritis with glucose- 6-phosphate dehydrogenase deficiency—results from a case-control study. G6PD and Rheumatoid Arthritis
1172PDF: 874HTML: 110 -
HEPATITIS C VIRUS INFECTION AND LYMPHOMA
1069PDF: 565HTML: 7880 -
“Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency. Hemolysis by Hemolysis and G6PD deficiency.
1556PDF: 1014HTML: 372







